چکیده (انگلیسی):

The practice of administering sublingual immunotherapy for respiratory allergy is gaining more and more diffusion
worldwide as a consequence of the robust demonstration of clinical efficacy and safety provided by recent
high-powered and well-designed studies, confirming for individual seasonal allergens the results of previous
metanalyses in adult and pediatric populations. Preliminary evidence derives from recent rigorous trials on perennial
allergens, like house dust mites, and specifically designed studies addressed the benefits on asthma.
Emerging research suggests that SLIT may have a future role in other allergic conditions such as atopic dermatitis,
food, latex and venom allergy. Efforts to develop a safer and more effective SLIT for inhalant allergens
have led to the development of allergoids, recombinant allergens and formulations with adjuvants and substances
targeting antigens to dendritic cells that possess a crucial role in initiating immune responses. The high
degree of variation in the evaluation of clinical effects and immunological changes requires further studies to
identify the candidate patients to SLIT and biomarkers of short and long term efficacy. Appropriate management
strategies are urgently needed to overcome the barriers to SLIT compliance.